Loading data for BOLT — first visit, this takes a few seconds.

Alert

Bolt Biotherapeutics Inc. (BOLT)

NasdaqCM: BOLT · Real-Time Price · USD

3.79

+0.00 (0.00%)

At close: Aug 26, 2026, 8:00 PM

3.88

-1.02%

After-hours: 4:10 PM

The price, the headline numbers and the latest news, in one place.

0.00% (1D)

No data available

Bid	2.7
Market Cap	7.55M
Revenue (ttm)	4.7M
Net Income (ttm)	-28.74M
	1.08
	-16.51
	n/a
	-0.19
P/B (ttm)	0.60
P/S (ttm)	1.61
Earnings Date	Aug 14, 2025

Ask	4.86
Volume	919
Avg. Volume (20D)	24,949
Open	3.79
Previous Close	3.79
Day's Range	3.79 - 3.79
52-Week Range	3.13 - 7.20
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About BOLT

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 5, 2021

Employees 23

Stock Exchange NasdaqCM

Ticker Symbol BOLT

Website https://www.boltbio.com

Full Company Profile

Financial Performance

In 2025, Bolt Biotherapeutics's revenue was 7.7M, an increase of 0.07% compared to the previous year's 7.69M. Earnings were -33.38M, a decrease of -47.12%.

Financial Statements

Earnings Surprise

Bolt Biotherapeutics has released their quarterly earnings on Aug 11, 2026:

Revenue of $26K misses estimates by $0, with -97.87% YoY decline.
EPS of -4.57 exceeds estimates by 16.49, with 21.21% YoY growth.

Next Earnings Release

Bolt Biotherapeutics Inc. is scheduled to release its earnings on Aug 14, 2025, after market closes.
Analysts project revenue of ... Upgrade

News

2 weeks ago · Zacks

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -53.87% and -99.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago · Zacks

Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates

Oculis Holding AG (OCS) delivered earnings and revenue surprises of +58.33% and +49.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

4 weeks ago · Zacks

Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of +20.00% and +1.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

3 months ago · Zacks

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -51.23% and -98.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

5 months ago · Zacks

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +10.70% and +150.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the st...

Page 1 of 2

Bolt Biotherapeutics Inc. (BOLT)